Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.

Cyclin-dependent kinases (CDKs) contribute to the cancer hallmarks of uncontrolled proliferation and increased survival. As a result, over the last two decades substantial efforts have been directed towards identification and development of pharmaceutical CDK inhibitors. Insights into the biological...

全面介紹

書目詳細資料

發表在:	PLoS ONE
Main Authors:	Sheelagh Frame, Chiara Saladino, Craig MacKay, Butrus Atrash, Peter Sheldrake, Edward McDonald, Paul A Clarke, Paul Workman, David Blake, Daniella Zheleva
格式:	Article
語言:	英语
出版:	Public Library of Science (PLoS) 2020-01-01
在線閱讀:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0234103&type=printable